NeuroVive: NeuroVive to present at the 3rd Annual Traumatic Brain Injury Conference in Washington DC
Lund (Sweden) – March 4th, 2013, NeuroVive Pharmaceutical AB, a leading mitochondrial medicine company, announces that Mikael Brönnegård, Chief Executive Officer, will present an overview of its clinical trial programme for NeuroSTAT®, a cyclophilin inhibitor for the treatment of severe traumatic brain injury, at the 3rd Annual Traumatic Brain Injury Conference (www.tbiconference.com) on Wednesday March 6th, 2013 at 11.25 EST at the Sheraton Crystal City Hotel in Washington DC.NeuroVive has launched a clinical trial programme to assess NeuroSTAT®’s potential to reduce secondary tissue